WGS

GeneDx Holdings Corp.

$68.74

+3.70% 2026-10-20

Healthcare

1M 3M 6M 1Y 2Y

WGSSPY

+5.8%

-32.0%

+11.5%

+0.9%

YTD

-47.1%

-45.9%

Live chart

Loading live chart…

What they do

GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing.

Healthcare · Diagnostics & Research

Grades vs sector

Momentum

Not enough data yet

–

Percentile within its GICS sector across the S&P 1500.

Growth

Not enough data yet

–

Percentile within its GICS sector across the S&P 1500.

Value

Not enough data yet

–

Percentile within its GICS sector across the S&P 1500.

Profitability

Not enough data yet

–

Percentile within its GICS sector across the S&P 1500.

Revisions

Not enough data yet

–

30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Our models

Not held by any of our 5 live models right now.

Quality Growth

not ranked (outside this model's universe or screens)

Momentum Top 15

not ranked (outside this model's universe or screens)

Momentum Blend

not in the current book

New Highs Growth

not ranked (outside this model's universe or screens)

Conviction 20

not in the current book

News

More news

Sector Update: Healthcare Stocks Gain Late Afternoon

MT Newswires · 20h ago

Sector Update: Healthcare Stocks Gain Tuesday Afternoon

MT Newswires · 22h ago

GeneDx to Add Long-Read Whole Genome Sequencing to Testing Portfolio

MT Newswires · Oct 20

GeneDx Expands Diagnostic Leadership with Long-Read Genome Sequencing, Advancing Rare Disease Diagnosis

Business Wire · Oct 20

GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026

Business Wire · Oct 19

Key stats

Market cap$2.1B

P/E (trailing)–

P/E (forward)57.4

52-week range32.21 – 170.87

Revenue growth (YoY, latest qtr)+11.4%

Dividend yield0.00%

Analyst consensusStrong Buy (8)

Mean price target$93.50 (+36%)

Valuation and fundamentals

Valuation & fundamentals

Bottom line

No cash-flow valuation

Model read-out from the numbers below, not advice. Score +0 (DCF counts double).

•Piotroski F-score6/9

▼Altman Z1.7 (distress)

▲Analyst target+36% (8 analysts)

Discounted cash flow

Trailing free cash flow is negative or missing, so a cash-flow DCF isn't meaningful by default. You can enter your own assumptions below.

Reverse DCFfor context, not a signal

Trailing free cash flow is zero or negative, so there's no growth rate to solve for. The price is betting on a turnaround to positive cash flow.

Edit assumptions · recalculates instantly

Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.97 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs sector

Forward EPS $1.20 vs trailing $-3.63. Forward P/E uses analysts' next-12-month estimate.

Backlog (remaining performance obligations)

RPO

$10.2M

as of 2021-12-31

vs a year ago

–

YoY

× TTM revenue

0.02×

coverage

21-12

Contracted revenue not yet recognized, from SEC filings (XBRL tag RevenueRemainingPerformanceObligation).

Quality & financial health

Gross margin

69.4%

Operating margin

-20.3%

FCF margin

-16.7%

Net margin

-23.4%

Return on equity

-43.5%

Return on invested capital

-35.0%

Net debt / EBITDA

–

Current ratio

3.3×

Interest cover

-30.8×

Cash conversion (OCF/NI)

–

Piotroski F-score 6/9 · last two fiscal years

✗ Positive net income✓ Positive operating cash flow✓ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✗ Current ratio improved✗ No share dilution✓ Gross margin improved✓ Asset turnover improved

Altman Z-score 1.7 (distress zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.

Analysts

Mean target

$94

+36%

Analysts

Strong Buy

Range

$83–$103

low – high

● price · ◆ mean target

Annual history

FY	Revenue	Net income	Free cash flow
2025	$427.5M	$-21.0M	$14.3M
2024	$305.4M	$-52.3M	$-34.0M
2023	$202.6M	$-175.8M	$-185.4M
2022	$234.7M	$-549.0M	$-326.3M
2021	$212.2M	$-245.4M	$-199.8M
2020	$179.3M	$-241.3M	$-117.2M

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +22.1%.

Earnings

Next report: 2026-10-27 · after close · EPS est 0.07

EstimateActual (beat)Actual (miss)

Report	EPS est	Actual	Surprise
2026-08-03	-0.19	0.01	+105.3%
2026-05-04	-0.02	-0.28	-1407.8%
2026-02-23	0.12	0.14	+16.7%
2025-10-28	0.42	0.49	+15.9%
2025-07-29	0.11	0.50	+371.7%
2025-04-30	0.09	0.27	+215.2%
2025-02-18	0.10	0.64	+514.9%
2024-10-29	-0.21	0.04	+120.2%

Quarterly revenue

Quarter	Revenue	YoY
2026-06-30	$114.4M	+11.4%
2026-03-31	$102.3M	–
2025-12-31	$121.0M	–
2025-09-30	$116.7M	–
2025-06-30	$102.7M	–

Analyst actions

Guggenheim

2026-10-01 · main

Buy → Buy
PT $83

Canaccord Genuity

2026-08-04 · main

Buy → Buy
PT $90

BTIG

2026-08-04 · reit

Buy → Buy
PT $90

Guggenheim

2026-06-29 · main

Buy → Buy
PT $74

Piper Sandler

2026-06-23 · main

Overweight → Overweight
PT $63

Canaccord Genuity

2026-05-05 · main

Buy → Buy
PT $75

Insider trades

Stueland Katherine

Director, CHIEF EXECUTIVE OFFICER · 2026-09-16

SELL
$155.3K

Stueland Katherine

Director, CHIEF EXECUTIVE OFFICER · 2026-09-16

SELL
$14.1K

Stueland Katherine

Director, CHIEF EXECUTIVE OFFICER · 2026-09-16

SELL
$147.8K

Stueland Katherine

Director, CHIEF EXECUTIVE OFFICER · 2026-09-16

SELL
$406.9K

Stueland Katherine

Director, CHIEF EXECUTIVE OFFICER · 2026-09-16

SELL
$300.8K

Feeley Kevin